4502 JP3463000004

Report

End-of-day quote Japan Exchange - 04/16
3704	JPY		-0.30%

04/14

CENTOGENE N : Extends Diagnostics Testing Partnership With Takeda

04/08

Japan shares slip on coronavirus concerns

04/07

Japan stocks fall on virus woes, but M&As lift some industrials

Summary

Quotes 5-day view End-of-day quote.

End-of-day quote Japan Exchange

04/12/2021	04/13/2021	04/14/2021	04/15/2021	04/16/2021	Date
3754	3716	3701	3715	3704	Last
4182300	6712800	5484000	3577800	4483900	Volume
+0.11%	-1.01%	-0.40%	+0.38%	-0.30%	Change

Financials

Sales 2021	3 217 B 29 561 M 29 561 M
Net income 2021	262 B 2 410 M 2 410 M
Net Debt 2021	4 096 B 37 642 M 37 642 M
P/E ratio 2021	25,3x
Yield 2021	4,86%

Sales 2022	3 239 B 29 763 M 29 763 M
Net income 2022	368 B 3 385 M 3 385 M
Net Debt 2022	3 568 B 32 786 M 32 786 M
P/E ratio 2022	16,1x
Yield 2022	4,86%

Capitalization	5 795 B 53 250 M 53 257 M
EV / Sales 2021	3,07x
EV / Sales 2022	2,89x
Nbr of Employees	47 495
Free-Float	99,0%

More Financials

Company

Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - sale of services. Net sales are distributed geographically as follows: Japan (18%), Asia (5%), the...

Sector

Pharmaceuticals

Calendar

05/11

Earnings Release

More about the company

Notations Surperformance© of Takeda Pharmaceutical Company Limited

Trading Rating :

Investor Rating :

More Ratings

All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED

04/14	CENTOGENE N : Extends Diagnostics Testing Partnership With Takeda	MT
04/08	Japan shares slip on coronavirus concerns	RE
04/07	Japan stocks fall on virus woes, but M&As lift some industrials	RE
04/07	TAKEDA PHARMACEUTICAL : to Host Wave 1 Pipeline Market Opportunity Conference C..	AQ
04/07	KAMADA : Amends GLASSIA License Contract with Takeda	MT
04/06	STREET COLOR : Takeda Pharmaceutical Reportedly Suspends Development of Plasma T..	MT
04/05	Japanese shares fall on profit booking, checking U.S. rates	RE
04/05	SECTOR UPDATE : Health Care Stocks Scratch Out Slim Gains	MT
04/05	UPDATE : Molecular Templates Scraps Experimental MT-3724 Drug, Takes Over Takeda..	MT
04/05	SECTOR UPDATE : Health Care Stocks Advancing This Afternoon	MT
04/05	TAKEDA PHARMACEUTICAL : Molecular Templates to Take Over Takeda's Myeloma Treat..	MT
04/05	Takeda Pharmaceutical Alliance's Clinical Trial Fails to Meet Endpoint	MT
04/05	Japanese shares end higher on strong U.S. job data, SoftBank jumps	RE
04/04	Japanese shares rise as strong U.S. job data lifts sentiment, index heavyweig..	RE
04/02	TAKEDA PHARMACEUTICAL : Topline Results from NIH-Sponsored Clinical Trial of In..	PU

More news

News in other languages on TAKEDA PHARMACEUTICAL COMPANY LIMITED

04/09	Pump / dump #6
04/08	TOKYO STOCK EXCHANGE : Borsa Tokyo chiude in calo su timori coronavirus
04/01	TAKEDA PHARMACEUTICAL : organiza una conferencia telefónica sobre sus productos..
04/01	TAKEDA PHARMACEUTICAL : veranstaltet Telefonkonferenz zu Marktchancen der Welle..
04/01	TAKEDA PHARMACEUTICAL : organise une téléconférence sur ses produits en dévelop..

More news

Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED

2020	TAKEDA PHARMACEUTICAL : Japan's Takeda says drug pipeline to lift sales to $48 ..	RE
2018	Takeda clears key hurdle as investors back $59 billion Shire deal	RE
2018	Takeda investors back $59 billion Shire deal, but wary of debt load	RE

More recommendations

Provided by Scoopnest.com

Analysis

Takeda Pharmaceutical : Japan's Takeda says drug pipeline to lift sales to $48 billion in next decade

More Must read

Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED

Duration : Period :

Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED

	Short Term	Mid-Term	Long Term
Trends	Bearish	Neutral	Bullish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	BUY
Number of Analysts	14
Average target price	5 197,86 JPY
Last Close Price	3 704,00 JPY
Spread / Highest target	86,3%
Spread / Average Target	40,3%
Spread / Lowest Target	10,7%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Christophe Weber	President, CEO & Representative Director
Constantine Saroukos	Chief Financial Officer & Director
Andrew S. Plump	Director, Research & Development President
Michael E. Mendelsohn	Chief Medical & Scientific Officer
Mwana Lugogo	Chief Ethics & Compliance Officer

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

TAKEDA PHARMACEUTICAL COMPANY LIMITED	-1.36%	53 452



JOHNSON & JOHNSON	1.91%	422 260
ROCHE HOLDING AG	0.16%	289 178
PFIZER INC.	0.98%	209 739
NOVARTIS AG	-3.73%	197 072
MERCK & CO., INC.	-6.28%	194 049

More Results